» Articles » PMID: 12483218

Selective Cognitive Dysfunction in Acetylcholine M1 Muscarinic Receptor Mutant Mice

Overview
Journal Nat Neurosci
Date 2002 Dec 17
PMID 12483218
Citations 199
Authors
Affiliations
Soon will be listed here.
Abstract

Blockade of cholinergic neurotransmission by muscarinic receptor antagonists produces profound deficits in attention and memory. However, the antagonists used in previous studies bind to more than one of the five muscarinic receptor subtypes. Here we examined memory in mice with a null mutation of the gene coding the M1 receptor, the most densely distributed muscarinic receptor in the hippocampus and forebrain. In contrast with previous studies using nonselective pharmacological antagonists, the M1 receptor deletion produced a selective phenotype that included both enhancements and deficits in memory. Long-term potentiation (LTP) in response to theta burst stimulation in the hippocampus was also reduced in mutant mice. M1 null mutant mice showed normal or enhanced memory for tasks that involved matching-to-sample problems, but they were severely impaired in non-matching-to-sample working memory as well as consolidation. Our results suggest that the M1 receptor is specifically involved in memory processes for which the cortex and hippocampus interact.

Citing Articles

Distinct Effects of Olanzapine Depot Treatment on Behavior and Muscarinic M1 Receptor Expression in the Triple-Hit Wisket Rat Model of Schizophrenia.

Horvath G, Ducza E, Adlan L, Buki A, Kekesi G Genes Brain Behav. 2025; 24(1):e70015.

PMID: 39844699 PMC: 11754962. DOI: 10.1111/gbb.70015.


Thyroid Hormone Neuroprotection Against Perfluorooctane Sulfonic Acid Cholinergic and Glutamatergic Disruption and Neurodegeneration Induction.

Moyano P, Guzman G, Flores A, Garcia J, Guerra-Menendez L, Sanjuan J Biomedicines. 2024; 12(11).

PMID: 39595009 PMC: 11591898. DOI: 10.3390/biomedicines12112441.


The potential of muscarinic M and M receptor activators for the treatment of cognitive impairment associated with schizophrenia.

Yohn S, Harvey P, Brannan S, Horan W Front Psychiatry. 2024; 15:1421554.

PMID: 39483736 PMC: 11525114. DOI: 10.3389/fpsyt.2024.1421554.


A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.

Tobin A Nat Rev Drug Discov. 2024; 23(10):743-758.

PMID: 39143241 DOI: 10.1038/s41573-024-01007-1.


Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.

Poon M, Lorrain K, Stebbins K, Edu G, Broadhead A, Lorenzana A Proc Natl Acad Sci U S A. 2024; 121(32):e2407974121.

PMID: 39083422 PMC: 11317586. DOI: 10.1073/pnas.2407974121.